MAP2K7 and glioma: Since the RAS-RAF-MEK-ERK and PI3K-AKT/PKB-mTOR pathways exhibit excessive activity (which increases the resistance of gliomas to pharmacotherapy), the molecularly targeted therapy, which targets the transmitter proteins of these signaling pathways, appears to be a promising treatment option [28].